NewsRoom Articles - Page 1328 of 1335

WednesdayAug 17, 2016 3:49 pm

Mondelez International, Inc. (MDLZ) Enters Licensing Agreement for Cadbury-Branded Biscuits

In a recent news release, Mondelez International, Inc. (NASDAQ: MDLZ), a global snacking powerhouse, announced an agreement with Burton’s Biscuit Company that will, pending regulatory approval, enable the company to manufacture, market and sell Cadbury-branded biscuits in a number of international markets, including the UK, France, Ireland, North America and Saudi Arabia. This landmark announcement is expected to facilitate accelerated biscuit growth for Mondelez in key markets around the globe, providing a platform to expand upon its position as a world leader in biscuits and chocolate. “Ownership of the Cadbury biscuits license offers us exciting opportunities to accelerate global growth…

WednesdayAug 17, 2016 9:02 am

The ONE Group Hospitality, Inc. (STKS) Signs $3 Million Loan Agreement

On Friday August 12, 2016, the ONE Group Hospitality, Inc. (NASDAQ: STKS) disclosed that it had issued an unsecured 5-year promissory note to Anson Investments Master Fund LP, the consideration for which is $3 million to be used for development. Interest on the note is payable quarterly at an annual rate of 10 percent, with the first payment due on September 30, 2016. The maturity date of the note is August 11, 2021. Under the terms of the loan agreement, the ONE Group Hospitality, Inc. has issued a warrant that gives Anson Investments Master Fund LP the right, but not…

TuesdayAug 16, 2016 11:40 am

Misonix, Inc. (MSON) Teams with SonoSpine, LLC to Advance Ultrasonic Technology

In a recent news release, Misonix, Inc. (NASDAQ: MSON), a leading manufacturer and marketer of therapeutic ultrasonic medical devices, announced its entry into a partnership with SonoSpine, LLC, an international neurosurgical practice specializing in ultrasonic spine surgery. Through this agreement, the two companies will look to leverage innovative devices and a revolutionary approach to spine surgery to accelerate the development and application of next generation ultrasonic surgery. Misonix will be granted access to SonoSpine’s clinical facilities in order to gain insight into ultrasonic therapies from the surgeon’s perspective, and the two companies will create a joint clinical database to support…

TuesdayAug 16, 2016 9:59 am

Cellectar Biosciences, Inc. (CLRB) Announces Corporate Highlights and Financial Results for Q2 2016

Cellectar Biosciences, Inc. (NASDAQ: CLRB) recently announced (http://nnw.fm/I70Ox) its corporate highlights for this quarter and financial results for Q2 2016, which ended on June 30 of this year. One of the company’s key accomplishments was the issuance of several patents from USPTO, including CLR 131 and other radiotherapeutics used in the treatment of cancerous cells, as well as the CLR 1600 series. In addition to these, the company shared the results of its preclinical study of 1602, and announced the completion of the first phase of the NCI SBIR fast track grant. CLRB also closed $8 million in financing and…

TuesdayAug 16, 2016 9:36 am

Monaker Group, Inc. (MKGI) Enters Agreement with Trisept Solutions to Fuel Growth

Before the opening bell, Monaker Group, Inc. (OTCQB: MKGI) announced a new agreement with Trisept Solutions, a division of The Mark Travel Corporation. Through this partnership, Trisept will both power Monaker’s flagship NextTrip.com brand with its Synapse travel merchandising platform and distribute its alternative lodging inventory through VAX VacationAccess, Trisept’s premier travel agent portal. This agreement is expected to fuel NextTrip’s forward growth by enabling expanded product offerings and distribution in the months to come. “Trisept has the most advanced technology available for leisure vacation packaging today,” Bill Kerby, chairman and chief executive officer of Monaker, stated in this morning’s…

MondayAug 15, 2016 10:18 am

Celsion Corporation (CLSN) and Zhejiang Hisun Pharmaceutical Company Expand Partnership with GEN-1 Agreement

On Tuesday August 8, 2016, Lawrenceville, New Jersey-based Celsion Corporation (NASDAQ: CLSN), a company focused on developing a portfolio of innovative cancer treatments, announced the commencement of a Technology Transfer, Manufacturing and Commercial Supply Agreement with Zhejiang Hisun Pharmaceutical Co. Ltd., a leading pharmaceutical company in China, relating to the production for clinical and commercial purposes of GEN-1, Celsion’s proprietary gene mediated IL-12 immunotherapy. The agreement comes four years after a similar one for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. The agreement gives Celsion a domestically-based partner as it engages with the China Food and Drug Administration (CFDA)…

MondayAug 15, 2016 9:31 am

Collectors Universe, Inc. (CLCT) Enters Multi-Year Agreement with Leading Chinese Distributor of Gold and Silver Products

Collectors Universe, Inc. (NASDAQ: CLCT), a leading provider of value-added services to the high-value collectibles market, recently announced that its subsidiary, Collectors Universe (Shanghai) Company Limited, has entered into a multi-year deal with Guojin Gold Co, Ltd. (“Guojin”), a distributor of gold and silver products in China. Under the terms of this deal, CLCT’s Professional Coin Grading Service (PCGS) division will provide coin grading services to Guojin beginning in the second half of 2016 and continuing through 2020. Guojin will leverage existing bank distribution channels to dispense the graded coin products. “Our agreement with Guojin demonstrates the significant progress we…

FridayAug 12, 2016 12:24 pm

Sorrento Therapeutics, Inc. (SRNE) Finalizes Private Placements worth $150 Million

On April 4, 2016, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced that it entered into definitive agreements for up to $150 million with institutional investors and Yuhan Corporation, the company’s strategic corporate partner. Most recently, the agreements escalated and were finalized on private placements of common stocks and warrants worth $150 million. Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing safe and efficient therapies for cancer and other medical requirements, as well as for autoimmune, inflammation, and oncology related diseases. In the news release, president and CEO of Sorrento Therapeutics, Inc., Dr. Henry Ji, stated, “The completion of this significant…

FridayAug 12, 2016 12:11 pm

Comtech Telecommunications Corp. (CMTL) to Supply U.S. Army with Hardware

Comtech Telecommunications Corp. (NASDAQ:CMTL) recently announced that it will be supplying the U.S. Army with Secret Internet Protocol Router and Non-Secure Internet Protocol Router Access Point (SNAP) Very Small Aperture Terminal (VSAT) satellite systems. The announcement came after its Government Solutions unit received $7.6 million in funding. Comtech Telecommunications Corp. specializes in designing, developing, manufacturing, and marketing unique and innovative communications systems and services. The company’s target market does not stop at the military; CMTL’s customer base is varied and includes commercial and government organizations worldwide involved in the communications industry. In a recent news release, Dr. Stanton Sloane, president…

ThursdayAug 11, 2016 3:10 pm

Aldeyra Therapeutics (ALDX) Discloses Promising Outcome from Clinical Trials of Topical Dermatologic NS2

On Tuesday, August 9, 2016, Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a biotechnology company involved in the commercialization of products that treat diseases thought to be related to endogenous aldehydes, made public the results of a randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermatologic NS2 for the treatment of the dermal manifestations of Sjögren-Larsson Syndrome (SLS). The company, which is based in Lexington, Massachusetts, first became aware of SLS in 2012 and made the decision to employ its knowledge of aldehyde traps to combat the disease. The encouraging conclusion of these clinical trials marks, therefore, a major milestone for Aldeyra…

Financial news and publishing for public and private companies

Contact us: 512.354.7000